Ivabradine induces RAD51 degradation, potentiating PARP inhibitor efficacy in non-germline BRCA pathogenic variant triple-negative breast cancer

Abstract Background Triple-negative breast cancer (TNBC) is an aggressive subtype lacking targetable proteins for treatment. PARP inhibitors (PARPi) are effective in BRCA-mutated cancers but have limited utility in non-germline BRCA-mutated (non-gBRCAm) TNBC. We hypothesized that inducing BRCAness b...

Deskribapen osoa

Xehetasun bibliografikoak

Egile Nagusiak:	Ho Tsoi, George Man Hong Leung, Ellen Pui Sum Man, Chan Ping You, Koei Ho Lam Cheung, Kelvin Yuen Kwong Chan, Chun Gong, Michael Shing Yan Huen, Ui Soon Khoo
Formatua:	Artigo
Hizkuntza:	Inglês
Argitaratua:	BMC 2025-08-01
Saila:	Journal of Translational Medicine
Gaiak:	Breast cancer BRCAness Ivabradine Olaparib Synthetic lethality Targeted therapy
Sarrera elektronikoa:	https://doi.org/10.1186/s12967-025-06902-8
Etiketak:	Etiketa erantsi Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!